TY - JOUR
T1 - Masked hypertension
T2 - Evidence of the need to treat
AU - Ogedegbe, Gbenga
AU - Agyemang, Charles
AU - Ravenell, Joseph E.
N1 - Funding Information:
Acknowledgment Drs. Ogedegbe’s work is supported by funding from the National Institutes of Health (R01 HL078566 and R01 HL087301). Dr. Ravenell’s work is supported by the American Heart Association Pharmaceutical Roundtable Award (Grant #0675069N) and the Robert Wood Johnson Foundation Amos Medical Faculty Development Award (Grant #66731).
PY - 2010/10
Y1 - 2010/10
N2 - The diagnosis of masked hypertension has been made easier with the widespread availability of home blood pressure monitoring devices with levels of accuracy comparable to ambulatory blood pressure monitoring. The negative impact of masked hypertension on cardiovascular morbidity and mortality is evidenced by numerous well-designed clinic-based and population-based studies. The relationship of masked hypertension and target organ damage is also well documented. These two factors, combined with the robust evidence of reduced cardiovascular morbidity and mortality achieved with blood pressure treatment, makes the argument for actively identifying patients with masked hypertension and prescribing treatment similar to that for patients with sustained hypertension. In this paper, we review the evidence for the cardiovascular prognosis of masked hypertension compared with sustained hypertension, we review its impact on target organ damage, we propose an algorithm for the treatment of patients with masked hypertension, and we point out the pitfalls in adopting such an approach.
AB - The diagnosis of masked hypertension has been made easier with the widespread availability of home blood pressure monitoring devices with levels of accuracy comparable to ambulatory blood pressure monitoring. The negative impact of masked hypertension on cardiovascular morbidity and mortality is evidenced by numerous well-designed clinic-based and population-based studies. The relationship of masked hypertension and target organ damage is also well documented. These two factors, combined with the robust evidence of reduced cardiovascular morbidity and mortality achieved with blood pressure treatment, makes the argument for actively identifying patients with masked hypertension and prescribing treatment similar to that for patients with sustained hypertension. In this paper, we review the evidence for the cardiovascular prognosis of masked hypertension compared with sustained hypertension, we review its impact on target organ damage, we propose an algorithm for the treatment of patients with masked hypertension, and we point out the pitfalls in adopting such an approach.
KW - Ambulatory blood pressure monitoring
KW - BP measurement
KW - Cardiovascular prognosis
KW - Home blood pressure monitoring
KW - Masked hypertension
KW - Out-of-office blood pressure measurement
KW - Self blood pressure measurement
KW - Target organ damage
UR - http://www.scopus.com/inward/record.url?scp=77958487585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958487585&partnerID=8YFLogxK
U2 - 10.1007/s11906-010-0140-4
DO - 10.1007/s11906-010-0140-4
M3 - Review article
C2 - 20694858
AN - SCOPUS:77958487585
SN - 1522-6417
VL - 12
SP - 349
EP - 355
JO - Current Hypertension Reports
JF - Current Hypertension Reports
IS - 5
ER -